Global Wellness Strategies Signs MDMA Supply Agreement with PharmAla Biotech
Global Wellness Strategies Signs MDMA Supply Agreement with PharmAla Biotech
The Shanti Therapeutics Focus on Chronic Pain Market with Psychedelics
山體療法專注於迷幻藥的慢性疼痛市場
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X4) (OTCQB: GWSFF) ("Global" or the "Company") and their Contract Research Organization ("CRO") iNGENü (a fully owned subsidiary of Cannvalate Pty Ltd) sign supply agreement with Canada-based PharmAla Biotech (CSE: MDMA) to supply GMP MDMA for the Shanti Therapeutics upcoming clinical trial.
温哥華,不列顛哥倫比亞省-(Newsfile Corp.-2022年2月10日)全球健康戰略公司(CSE:GWS)(證券交易所市場代碼:O3X4)(場外交易市場代碼:GWSFF)(“全球”或“公司”)及其合同研究組織(“CRO”)Ingenü(Cannvalate Pty Ltd的全資子公司)與總部設在加拿大的PharmAla Biotech(CSE:MDMA)簽署了供應協議,為Shanti治療公司即將進行的臨牀試驗供應GMP MDMA。
Global Wellness' Shanti Therapeutics is a first-in-class biotech utilizing the neuromodulation properties of MDMA (aka Ecstasy) to pre-emptively treat preoperative pain. Shanti has commenced a path to their clinical trial in 22 healthy volunteers comparing the pain tolerance threshold in patients who have had exposure to a proprietary dose and formulation of MDMA. This proof-of-concept clinical study is to gauge the effect size of an increase in the pain threshold in subjects who have been pre-emptively treated with MDMA. iNGENü was chosen as the Contract Research Organization (CRO), as they are a niche CRO specialized in novel psychedelic clinical trials.
Global Wellness的Shanti治療公司是一項一流的生物技術,利用MDMA(又名搖頭丸)的神經調節特性搶先治療術前疼痛。Shanti已經開始在22名健康志願者身上進行臨牀試驗,比較了接觸過專有劑量和MDMA配方的患者的疼痛耐受閾值。這項概念驗證臨牀研究旨在評估預先接受MDMA治療的受試者痛閾升高的影響大小。Ingenü被選為合同研究組織(CRO),因為他們是專門從事新型迷幻臨牀試驗的利基CRO。
"Biotechs face many roadblocks as a drug development journey begins. Choosing the right CRO can make or break a molecule's future and a bad selection can derail the most aggressive clinical trial. Developing an integrated, big-picture roadmap for a molecule and company can only work with a formidable CRO, as even a lucrative discovery is a challenging and expensive endeavor. Not only do we have both a strong CRO to guide the research and trials plus the recently formed alliance with PharmAla, but also another Canadian partner Pharmascience Inc. completes their MDMA orders, which is Canada's second largest manufacturer of generic and branded drugs and a tremendous milestone check mark for Shanti! These strategic partnerships are pivotal to the success of Shanti as the sponsor of the project and the discovery of a new molecule to solve the puzzle of chronic pain," said Meris Kott, CEO, Global Wellness Strategies Inc.
“隨着藥物開發之旅的開始,生物技術公司面臨着許多障礙。選擇正確的CRO可以決定一個分子的未來,而一個糟糕的選擇可能會使最具侵略性的臨牀試驗脱軌。為分子和公司制定一個完整的、宏偉的路線圖只能與強大的CRO合作,因為即使是一個有利可圖的發現也是一項具有挑戰性和昂貴的努力。我們不僅有一個強大的CRO來指導研究和試驗,而且最近與PharmAla建立了聯盟,而且另一個加拿大合作伙伴Pharmascience Inc.完成了他們的MDMA訂單,這是加拿大第二大仿製藥和品牌藥製造商,也是Shanti的一個巨大的里程碑複選標記!這些戰略夥伴關係對於Shanti作為該項目贊助商的成功以及發現一種新分子來解決慢性疼痛之謎至關重要。“Global Wellness Strategy Inc.首席執行官Meris Kott説。
"I'm thrilled that, as the first company to develop a full GMP MDMA value chain in North America, we can now help enable other companies such as Global Wellness Strategies," said Nick Kadysh, founding CEO, PharmAla Biotech. "Alleviating the backlog of clinical-grade MDMA for research will accelerate the entire Psychedelics category, and help bring MDMA in the mainstream. Over the coming months we will be working diligently to fulfill Global Wellness Strategies' needs, and support them as they move their research forward."
PharmAla Biotech的創始首席執行官尼克·卡迪什説:“我很高興,作為北美第一家開發完整的GMP MDMA價值鏈的公司,我們現在可以幫助其他公司,如全球健康戰略公司,”PharmAla Biotech的創始首席執行官尼克·卡迪什(Nick Kadysh)説。減少臨牀級MDMA用於研究的積壓將加速整個迷幻藥類別,並有助於將MDMA帶入主流。在接下來的幾個月裏,我們將努力滿足全球健康戰略的需求,並在他們推進研究的過程中支持他們。“
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a "regulatory first" organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. PharmAla has built what it believes to be North America's first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation.
PharmAla生物技術控股公司(CSE:MDMA)是一家專注於MDXX類分子(包括MDMA)的研究、開發和製造的生物技術公司。PharmAla的創立有兩個重點:緩解全球積壓的仿製藥、臨牀級MDMA,以實現臨牀試驗,並開發同類別的新藥。PharmAla是一個“監管優先”的組織,其成立的原則是隻有通過與監管機構的良好關係才能在迷幻藥行業取得真正的成功。PharmAla已經建立了它認為是北美第一條cGMP MDMA價值鏈,包括活性藥物成分(API)的GMP製造和藥物產品配方。
About Global Wellness Strategies
關於全球健康戰略
Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.
Global Wellness Strategy是一個潛在的推動者,在快速增長的健康消費品市場為高增長的公司提供財務、運營和管理方面的幫助。該公司的重點是全球保健、迷幻藥、真菌學、大麻和CBD,這些都是與醫療保健相關的目標公司。
For further information visit websites:
and
欲瞭解更多信息,請訪問以下網站:
和
Or Contact Meris Kott CEO 604.484.0355 or email to info@globalwellnessstrategies.com
或聯繫Meris Kott首席執行官604.484.0355,或發送電子郵件至info@globalwell nessstrategies.com
Further information about the Company is available on under the Company's profile.
欲瞭解更多有關該公司的信息,請訪問公司簡介。
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。本新聞稿中包含的某些陳述可能構成“前瞻性陳述”或“前瞻性信息”(統稱為“前瞻性信息”),因為這些術語在1995年“私人證券訴訟改革法”和類似的加拿大法律中使用。這些陳述與未來事件或未來表現有關。使用“可能”、“打算”、“預期”、“相信”、“將會”、“預計”、“估計”、“預期”以及與非歷史事實有關的類似表述和陳述,旨在識別前瞻性信息,並基於公司對此類未來事件的結果和時機的當前信念或假設。未來的實際結果可能會大不相同。特別是,本新聞稿包含與該公司的業務、其融資和某些公司變化有關的前瞻性信息。本新聞稿中包含的前瞻性信息是截至本新聞稿發佈之日的前瞻性信息,除非適用的證券法要求,否則公司沒有義務因新信息、未來事件或其他原因而更新或修改任何前瞻性信息。由於本文包含的風險、不確定性和假設,投資者不應過度依賴前瞻性信息。前述陳述明確限定了本文中包含的任何前瞻性信息。
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問